Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Dec;13(6):442-9.
doi: 10.1007/s11912-011-0193-9.

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond

Susana Banerjee  1 , Stan Kaye
Affiliations
Review

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond

Susana Banerjee et al. Curr Oncol Rep. 2011 Dec.

Abstract

Poly(ADP-ribose)polymerase (PARP) inhibitors are showing considerable promise for the treatment of BRCA mutation-associated ovarian and breast cancer. This approach exploits a synthetic lethal strategy to target the specific DNA repair pathway in cancers that harbor mutations in the BRCA1 or BRCA2 genes. Accumulating evidence suggests that PARP inhibitors may have a wider application in the treatment of sporadic, high-grade serous ovarian cancers and other cancers including endometrial cancer. In this review, we discuss the clinical development of PARP inhibitors in ovarian cancer and explore challenges that need to be addressed if the full potential of these agents is to be realized.

PubMed Disclaimer

References

    1. J Clin Oncol. 2002 Jan 15;20(2):463-6 - PubMed
    1. Nature. 2005 Apr 14;434(7035):917-21 - PubMed
    1. Nature. 2005 Apr 14;434(7035):913-7 - PubMed
    1. Nat Rev Cancer. 2005 Sep;5(9):689-98 - PubMed
    1. Nat Rev Cancer. 2004 Oct;4(10):814-9 - PubMed

Substances

LinkOut - more resources